VYNE Therapeutics Inc.

VYNE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$39,834-$28,452-$23,210-$73,329
Dep. & Amort.$4$0$72$109
Deferred Tax$0$0$0$1,525
Stock-Based Comp.$3,303$3,305$4,297$8,080
Change in WC$4,999$60$2,277$4,776
Other Non-Cash-$2,444-$254-$12,636$2,472
Operating Cash Flow-$33,972-$25,341-$29,200-$56,367
Investing Activities
PP&E Inv.-$117$0$0$0
Net Acquisitions$0$5,000$15,667$0
Inv. Purchases-$60,518-$62,354$0$0
Inv. Sales/Matur.$84,000$0$0$1,027
Other Inv. Act.$0$0$0$0
Investing Cash Flow$23,365-$57,354$15,667$1,027
Financing Activities
Debt Repay.$0$0$0-$36,432
Stock Issued$0$82,821$1,470$75,981
Stock Repurch.-$141$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$427$183$228
Financing Cash Flow-$141$82,394$1,653$39,777
Forex Effect$0$0$0$0
Net Chg. in Cash-$10,748-$301-$11,880-$15,563
Supplemental Information
Beg. Cash$30,674$30,975$42,855$58,418
End Cash$19,926$30,674$30,975$42,855
Free Cash Flow-$34,089-$25,341-$29,200-$56,367
VYNE Therapeutics Inc. (VYNE) Financial Statements & Key Stats | AlphaPilot